Affiliation:
1. Key Laboratory for Bio‐Electromagnetic Environment and Advanced Medical Theranostics School of Biomedical Engineering and Informatics Nanjing Medical University Nanjing 211166 P. R. China
2. Center for Data Science Zhejiang University Hangzhou 310058 P. R. China
3. Department of Urology The Second Affiliated Hospital of Nanjing Medical University Nanjing 210011 P. R. China
4. Nanjing Key Laboratory for Cardiovascular Information and Health Engineering Medicine Institute of Clinical Medicine Nanjing Drum Tower Hospital Medical School Nanjing University Nanjing 210093 P. R. China
Abstract
AbstractCistrome‐wide association studies (CWAS) are pivotal for identifying genetic determinants of diseases by correlating genetically regulated cistrome states with phenotypes. Traditional CWAS typically develops a model based on cistrome and genotype data to associate predicted cistrome states with phenotypes. The random effect cistrome‐wide association study (RECWAS), reevaluates the necessity of cistrome state prediction in CWAS. RECWAS utilizes either a linear model or marginal effect for initial feature selection, followed by kernel‐based feature aggregation for association testing is introduced. Through simulations and analysis of prostate cancer data, a thorough evaluation of CWAS and RECWAS is conducted. The results suggest that RECWAS offers improved power compared to traditional CWAS, identifying additional genomic regions associated with prostate cancer. CWAS identified 102 significant regions, while RECWAS found 50 additional significant regions compared to CWAS, many of which are validated. Validation encompassed a range of biological evidence, including risk signals from the GWAS catalog, susceptibility genes from the DisGeNET database, and enhancer‐domain scores. RECWAS consistently demonstrated improved performance over traditional CWAS in identifying genomic regions associated with prostate cancer. These findings demonstrate the benefits of incorporating kernel methods into CWAS and provide new insights for genetic discovery in complex diseases.
Funder
National Natural Science Foundation of China
Innovative Research Group Project of the National Natural Science Foundation of China